How long does it take for the treatment of glioma with ivonib/Tosuvo to be effective?

Ivosidenib (Ivosidenib) as an IDH1-targeting Innovative drugs based on mutation pathways are regarded as more targeted new options in the treatment of acute myeloid leukemia (AML), cholangiocarcinoma (CCA), and myelodysplastic syndrome (MDS). Since the drug affects the biological behavior of tumor cells by inhibiting the activity of mutated enzymes and reducing the accumulation of downstream metabolites, its onset of action is usually not as rapid as traditional chemotherapy, but closer to the rhythm of "metabolic remodeling therapy". In clinical practice, doctors generally believe that the effective period of ivonib is closely related to the patient's tumor grade, disease course, baseline imaging characteristics, and individual differences in drug metabolism. Therefore, the emergence of treatment effects has staged characteristics.

Most glioma patients treated with ivonib usually begin to experience imaging or symptom-level changes after approximately 8 to 12 weeks of treatment, such as changes in headache frequency, stabilization of local neurological symptoms, and decreases in tumor metabolism indicators. However, for some patients whose tumors progress slowly, the real benefit of the drug may only gradually appear after 3 to 6 months. This time difference is more due to the growth dynamics of the glioma itself and the action path of IDH1 inhibitory drugs.

In addition, in overseas clinical studies, it was also emphasized that the evaluation of the effect of ivonib in treating glioma cannot rely solely on short-term tumor volume changes, but rather focuses on comprehensive indicators such as "prolongation of tumor stability time", "improvement of metabolic indicators" and "maintenance of patient functional status". Some patients may still obtain long-term clinical benefit from reduced tumor activity even if they do not show significant radiographic shrinkage.

It is worth reminding that if symptoms fluctuate during treatment, it does not mean that the drug is ineffective. Professional organizations generally recommend continued periodic evaluation while avoiding premature interruption of treatment, which is also consistent with the long-term management of targeted IDH suppression.

Reference: https://www.tibsovo.com/